Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-1
Biotechnologies, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | BioHarvest Sciences Inc.
Entheon Adopts Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that it has elected to participate in the Coordinated Blanket Order 51-933 – Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order"), issued by the Canadian Securities Administrators, and adopts semi-annual financial reporting. This news release is being filed
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-11 6:18 PM EDT | Entheon Biomedical Corp.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone. "One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scien
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-09-10 7:15 AM EDT | Resverlogix Corp.
Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting"). A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled
2026-09-09 5:05 PM EDT | Noveris Health Sciences Inc.
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at
Biotechnologies, Pharmaceutique
2026-09-09 4:30 PM EDT | InMed Pharmaceuticals
Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé
Calgary, Alberta--(Newsfile Corp. - 9 septembre 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l'approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse des 16 juillet 2026 et 19 août 2026) (le « Placement
2026-09-09 2:37 PM EDT | Marvel Biosciences Corp.
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange ("TSXV") to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the "Offering"). The deadline by which the Company must file its final closing materials with the TSXV has been extend
2026-09-09 2:32 PM EDT | Marvel Biosciences Corp.
Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy
Boston, Massachusetts--(Newsfile Corp. - September 9, 2026) - Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today highlighted the publication of research conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research in Science Advances. The paper, entitled "Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dy
2026-09-09 2:27 PM EDT | Tevard Biosciences
Maxwell Biosciences Receives FDA Qualified Infectious Disease Product (QIDP) Designation for All-Cause Bacterial and Fungal Pneumonia
Austin, Texas--(Newsfile Corp. - September 8, 2026) - Maxwell Biosciences, a biotechnology company developing a new class of immune-inspired anti-infective therapeutics, today announced that on May 5, 2026, the U.S. Food and Drug Administration (FDA) granted Qualified Infectious Disease Product (QIDP) designation to MXB-22,510-SC, Maxwell's investigational parenteral injectable drug candidate for the treatment of community-acquired pneumonia (CAP) and hospital-acquired (HAP) or ventilator-ass
Biotechnologies, Pharmaceutique
2026-09-08 9:00 AM EDT | Maxwell Biosciences, Inc.
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials. "Keith has substantial experience supporting U.
Biotechnologies, Pharmaceutique
2026-09-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026 Company receives $3.15 million in VAT refunds into OS Therapies UK, Ltd. subsidiary, with an additional $7.2 million in refundable VAT an
2026-09-08 6:00 AM EDT | OS Therapies
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company'
Biotechnologies, Pharmaceutique, Santé
2026-09-08 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 202
Biotechnologies, Pharmaceutique, Santé
2026-09-04 6:00 PM EDT | Defence Therapeutics Inc.
MustGrow Announces Officer Appointment and Grant of DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 4, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company and that the board of directors of the Company has authorized and approved the grant of a total of 1,126,954 deferred share units of the Company ("DSUs") to directors (excluding the Company's Chief Excutive Officer an
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-09-04 7:00 AM EDT | MustGrow Biologics Corp.
Nextleaf Solutions Reports Fiscal Q3 2026 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented Canadian cannabis processor, released its financial results for the third quarter ended June 30, 2026. The quarter reflected sequential improvement in net revenue and a significant reduction in excise taxes, supported by a broadened product mix including non-excisable bulk sales and tolling services. Net r
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-09-03 5:01 PM EDT | Nextleaf Solutions Ltd.
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026. Dr Zak
Biotechnologies, Pharmaceutique, Santé
2026-09-03 7:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited. In the second quarter o
Technologies, Biotechnologies, Santé
2026-09-03 6:00 AM EDT | Restart Life Sciences Corp.
Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City. H.C.
Biotechnologies, Soins de santé et hôpitaux
2026-09-02 8:30 AM EDT | Envoy Medical, Inc.